References
- Schwartz DA, Loftus EV, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122(4):1–12. doi:https://doi.org/10.1053/gast.2002.32362.
- Gecse KB, Sebastian S, Hertogh G, Yassin NA, Kotze PG, Reinisch W, Spinelli A, Koutroubakis IE, Katsanos KH, Hart A, et al. Results of the Fifth Scientific Workshop of the ECCO [II]: clinical aspects of perianal fistulising Crohn’s disease—the unmet needs. J Crohns Colitis. 2016;10(7):758–765. doi:https://doi.org/10.1093/ecco-jcc/jjw039.
- Scharl M, Rogler G, Biedermann L. Fistulizing Crohn’s disease. Clin Transl Gastroenterol. 2017;8(7):e106. doi:https://doi.org/10.1038/ctg.2017.33.
- Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281–1290. doi:https://doi.org/10.1016/S0140-6736(16)31203-X.
- Molendijk I, Bonsing BA, Roelofs H, Peeters KCMJ, Wasser MNJM, Dijkstra G, van der Woude CJ, Duijvestein M, Veenendaal RA, Zwaginga -J-J, et al. Allogeneic bone marrow–derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2015;149(4):918–27 e6. doi:https://doi.org/10.1053/j.gastro.2015.06.014.
- Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, et al. Long-term efficacy and safety of stem cell therapy (cx601) for complex perianal fistulas in patients with crohn’s disease. Gastroenterology. 2018;154(5):1334–42 e4. doi:https://doi.org/10.1053/j.gastro.2017.12.020.
- Siegmund B, Feakins RM, Barmias G, Ludvig JC, Teixeira FV, Rogler G, Scharl M. Results of the fifth scientific workshop of the ecco (ii): pathophysiology of perianal fistulizing disease. J Crohns Colitis. 2016;10:377–386. doi:https://doi.org/10.1093/ecco-jcc/jjv228.
- Lovisa S, Genovese G, Danese S. Role of epithelial-to-mesenchymal transition in inflammatory bowel disease. J Crohns Colitis. 2019;13(5):659–668. doi:https://doi.org/10.1093/ecco-jcc/jjy201.
- Jiang H, Shen J, Ran Z. Epithelial-mesenchymal transition in crohn’s disease. Mucosal Immunol. 2018;11:294–303. doi:https://doi.org/10.1038/mi.2017.107.
- Bataille F, Klebl F, Rümmele P, Schroeder J, Farkas S, Wild PJ, Fürst A, Hofstädter F, Schölmerich J, Herfarth H, et al. Morphological characterisation of crohn’s disease fistulae. Gut. 2004;53:1314–1321. doi:https://doi.org/10.1136/gut.2003.038208.
- Bataille F, Rohrmeier C, Bates R, Weber A, Rieder F, Brenmoehl J, Strauch U, Farkas S, Fürst A, Hofstädter F, et al. Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohnʼs disease. Inflamm Bowel Dis. 2008;14(11):1514–1527. doi:https://doi.org/10.1002/ibd.20590.
- Scharl M, Weber A, Fürst A, Farkas S, Jehle E, Pesch T, Kellermeier S, Fried M, Rogler G. Potential role for SNAIL family transcription factors in the etiology of Crohnʼs disease-associated fistulae. Inflamm Bowel Dis. 2011;17(9):1907–1916. doi:https://doi.org/10.1002/ibd.21555.
- Scharl M, Frei S, Pesch T, Kellermeier S, Arikkat J, Frei P, Fried M, Weber A, Jehle E, Rühl A, et al. Interleukin-13 and transforming growth factor β synergise in the pathogenesis of human intestinal fistulae. Gut. 2013;62(1):63–72. doi:https://doi.org/10.1136/gutjnl-2011-300498.
- Frei SM, Pesch T, Lang S, Weber A, Jehle E, Vavricka SR, Fried M, Rogler G, Scharl M. A role for tumor necrosis factor and bacterial antigens in the pathogenesis of Crohnʼs disease–associated fistulae. Inflamm Bowel Dis. 2013;19(13):2878–2887. doi:https://doi.org/10.1097/01.MIB.0000435760.82705.23.
- Frei SM, Hemsley C, Pesch T, Lang S, Weber A, Jehle E, Rühl A, Fried M, Rogler G, Scharl M, et al. The role for dickkopf-homolog-1 in the pathogenesis of crohn’s disease-associated fistulae. PLoS One. 2013;8(11):e78882. doi:https://doi.org/10.1371/journal.pone.0078882.
- Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, Taylor CJ, Evans GS. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 1999;117(4):814–822. doi:https://doi.org/10.1016/S0016-5085(99)70339-2.
- Faubion WA, Fletcher JG, O’Byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, et al. EMerging BiomARKers in inflammatory bowel disease (EMBARK) study identifies fecal calprotectin, Serum MMP9, and Serum IL-22 as a novel combination of biomarkers for Crohn’s disease activity: role of cross-sectional imaging. Am J Gastroenterol. 2013;108(12):1891–1900. doi:https://doi.org/10.1038/ajg.2013.354.
- Kirkegaard T, Hansen A, Bruun E, Brynskov J. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with crohn’s disease. Gut. 2004;53:701–709. doi:https://doi.org/10.1136/gut.2003.017442.
- Goffin L, Fagagnini S, Vicari A, Mamie C, Melhem H, Weder B, Lutz C, Lang S, Scharl M, Rogler G, et al. Anti-mmp-9 antibody: a promising therapeutic strategy for treatment of inflammatory bowel disease complications with fibrosis. Inflamm Bowel Dis. 2016;22(9):2041–2057. doi:https://doi.org/10.1097/MIB.0000000000000863.
- van Haaften WT, Mortensen JH, Karsdal MA, Bay-Jensen AC, Dijkstra G, Olinga P. Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn’s disease. Aliment Pharmacol Ther. 2017;46(1):26–39. doi:https://doi.org/10.1111/apt.14092.
- de Bruyn M, Breynaert C, Arijs I, De Hertogh G, Geboes K, Thijs G, Matteoli G, Hu J, Van Damme J, Arnold B, et al. Inhibition of gelatinase b/mmp-9 does not attenuate colitis in murine models of inflammatory bowel disease. Nat Commun. 2017;8(1):15384. doi:https://doi.org/10.1038/ncomms15384.
- Schreiber S, Siegel CA, Friedenberg KA, Younes ZH,Seidler U, Bhandari BR, Wang K, Wendt E, McKevitt M, Zhao S, et al. A phase 2, randomized, placebo-controlled study evaluating matrix metalloproteinase-9 inhibitor, andecaliximab, in patients with moderately to severely active crohn’s disease. J Crohns Colitis. 2018;12:1014–1020.
- Chen H, Xu H, Luo L, Qiao L, Wang Y, Xu M, Li Y, Zhu P, Yang B. Thalidomide prevented and ameliorated pathogenesis of crohn’s disease in mice via regulation of inflammatory response and fibrosis. Front Pharmacol. 2019;10:1486. doi:https://doi.org/10.3389/fphar.2019.01486.
- Bruckner RS, Nissim-Eliraz E, Marsiano N, Nir E, Shemesh H, Leutenegger M, Gottier C, Lang S, Spalinger MR, Leibl S, et al. Transplantation of human intestine into the mouse: a novel platform for study of inflammatory enterocutaneous fistulas. J Crohns Colitis. 2019;13(6):798–806. doi:https://doi.org/10.1093/ecco-jcc/jjy226.
- Nagy N, Marsiano N, Bruckner RS, Scharl M, Gutnick MJ, Yagel S, Arciero E, Goldstein AM, Shpigel NY. Xenotransplantation of human intestine into mouse abdomen or subcutaneous tissue: novel platforms for the study of the human enteric nervous system. Neurogastroenterol Motil. 2018;30(3):e13212. doi:https://doi.org/10.1111/nmo.13212.
- Bauvois B. New facets of matrix metalloproteinases mmp-2 and mmp-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta. 2012;1825:29–36.
- Scharl M, Rogler G. Pathophysiology of fistula formation in crohn’s disease. World J Gastrointest Pathophysiol. 2014;5:205–212. doi:https://doi.org/10.4291/wjgp.v5.i3.205.
- Drygiannakis I, Valatas V, Sfakianaki O, Bourikas L, Manousou P, Kambas K, Ritis K, Kolios G, Kouroumalis E. Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts: implication in intestinal fibrosis. J Crohns Colitis. 2013;7(4):286–300. doi:https://doi.org/10.1016/j.crohns.2012.04.008.